Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

76.67
Delayed Data
As of Dec 09
 -0.55 / -0.71%
Today’s Change
73.31
Today|||52-Week Range
129.18
-39.07%
Year-to-Date
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
Dec 07 / Zacks.com - Paid Partner Content
Nivalis (NVLS) Cystic Fibrosis Study Misses Primary Endpoint
Nov 29 / Zacks.com - Paid Partner Content
The Worst American Stocks of 2016
Dec 07 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close77.22
Today’s open77.70
Day’s range76.28 - 79.67
Volume1,618,599
Average volume (3 months)1,719,778
Market cap$19.0B
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+26.43%
Earnings growth (this year)+169.58%
Earnings growth (next 5 years)+46.00%
Revenue growth (last year)+77.86%
P/E ratioNM
Price/Sales29.41
Price/Book20.09

Competitors

 Today’s
change
Today’s
% change
INCYIncyte Corp-2.25-2.19%
MYLMylan NV+0.45+1.25%
BMRNBiomarin Pharmaceuti...-0.83-0.99%
BAXBaxter International...+0.76+1.72%
Data as of 4:14pm ET, 12/09/2016

Financials

Next reporting dateFebruary 1, 2017
EPS forecast (this quarter)$0.27
Annual revenue (last year)$1.0B
Annual profit (last year)-$556.3M
Net profit margin-53.89%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Jeffrey M. Leiden
SVP &
GM-International Commercial Operations
Simon Bedson
Corporate headquarters
Boston, Massachusetts

Forecasts


Search for Jobs